Article    Table of Contents                    Full Text of this article    PDF of this article (PDFs free after 6 months)    Figures/Tables List    CME course  Services    Send comment/rapid response letter    Published comments/rapid response letters    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search    Get Permissions  Google Scholar    Search for Related Content  Social Bookmarking

What's this?

PubMed

Articles in PubMed by Author:    Sanderson, S.    Kinmonth, A.-L.    Related Articles in PubMed    PubMed Citation    PubMed

REVIEW

Narrative Review: Aspirin Resistance and Its Clinical Implications

Simon Sanderson, DPH; Jon Emery, PhD; Trevor Baglin, MD; and Ann-Louise Kinmonth, MD

1 March 2005 | Volume 142 Issue 5 | Pages 370-380

Aspirin is currently the most cost-effective drug for the secondary prevention of cardiovascular disease, but treatment failures are relatively common. Several factors have been linked to these recurrent vascular events in patients prescribed aspirin, including smoking, drug interactions, nonadherence, comorbid conditions, and aspirin resistance. The term aspirin resistance has been used to describe not only an absence of the expected pharmacologic effects of aspirin on platelets but also poor clinical outcomes, such as recurrent vascular events, in patients treated with aspirin. Aspirin resistance is perhaps more precisely understood as the phenomenon of measurable, persisting platelet activation that occurs in patients prescribed a therapeutic dose of aspirin and may underlie an unknown proportion of aspirin treatment failures. Key challenges for future research are to standardize a definition of aspirin resistance and to compare whether different measures of platelet activation, either alone or in combination, independently predict cardiovascular events. These challenges must be met before researchers conduct studies to assess the clinical utility of testing on patient outcomes and cost-effective prescribing.

Author and Article Information

From University of Cambridge, Addenbrooke's Hospital, and Institute of Public Health, Cambridge, United Kingdom; and University of Western Australia, Claremont, Western Australia, Australia.

Potential Financial Conflicts of Interest: None disclosed.

Requests for Single Reprints: Simon Sanderson, DPH, University of Cambridge, Strangeways Research Laboratory, Wort's Causeway, Cambridge CB1 8RN, United Kingdom; e-mail, simon.sanderson{at}srl.cam.ac.uk.

Current Author Addresses: Dr. Sanderson: University of Cambridge, Strangeways Research Laboratory, Wort's Causeway, Cambridge CB1 8RN, United Kingdom.

Dr. Emery: University of Western Australia, 328 Stirling Highway, Claremont, Western Australia 6010, Australia.

Dr. Baglin: Clinical Haematology, Addenbrooke's National Health Service Trust, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, United Kingdom.

Dr. Kinmonth: Department of Public Health and Primary Care, Institute of Public Health, Robinson Way, Cambridge CB2 2QQ, United Kingdom.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Facebook

Reddit

Technorati

Twitter

This article has been cited by other articles:

				N. Zimmermann, E. Gams, and T. Hohlfeld Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent. Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 93 - 108. [Abstract] [Full Text] [PDF]

				A. Natarajan, A. G Zaman, and S. M Marshall Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents Diabetes and Vascular Disease Research, June 1, 2008; 5(2): 138 - 144. [Abstract] [PDF]

				A. Y. Gasparyan, T. Watson, and G. Y.H. Lip The Role of Aspirin in Cardiovascular Prevention: Implications of Aspirin Resistance J. Am. Coll. Cardiol., May 13, 2008; 51(19): 1829 - 1843. [Abstract] [Full Text] [PDF]

				S. Tseeng and R. Arora Aspirin Resistance: Biological and Clinical Implications Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2008; 13(1): 5 - 12. [Abstract] [PDF]

				R. F. Storey Variability of response to antiplatelet therapy Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A21 - A27. [Abstract] [Full Text] [PDF]

				J. D. Snoep, M. M. C. Hovens, J. C. J. Eikenboom, J. G. van der Bom, and M. V. Huisman Association of Laboratory-Defined Aspirin Resistance With a Higher Risk of Recurrent Cardiovascular Events: A Systematic Review and Meta-analysis Arch Intern Med, August 13, 2007; 167(15): 1593 - 1599. [Abstract] [Full Text] [PDF]

				A. Undas, K. E. Brummel-Ziedins, and K. G. Mann Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions Blood, March 15, 2007; 109(6): 2285 - 2292. [Abstract] [Full Text] [PDF]

				A Blann Antiplatelet therapy and the vascular tree Heart, January 1, 2006; 92(1): 3 - 4. [Full Text] [PDF]

				S. Isbir, K. Ak, and N. Aksoy Platelet function tests predict bleeding and thrombotic events after off-pump coronary bypass grafting Eur. J. Cardiothorac. Surg., September 1, 2005; 28(3): 514 - 514. [Full Text] [PDF]

				J. W. Norris Antiplatelet Agents in Secondary Prevention of Stroke: A Perspective Stroke, September 1, 2005; 36(9): 2034 - 2036. [Abstract] [Full Text] [PDF]

				K. K Dhatariya Aspirin for everyone over 50?: Don't forget aspirin resistance BMJ, July 16, 2005; 331(7509): 161 - 161. [Full Text]

				C. Mulrow and M. Pignone An Editorial Update: Should She Take Aspirin? Ann Intern Med, June 7, 2005; 142(11): 942 - 943. [Full Text] [PDF]

				P. M Ridker, N. R. Cook, I-M. Lee, D. Gordon, J. M. Gaziano, J. E. Manson, C. H. Hennekens, and J. E. Buring A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women N. Engl. J. Med., March 31, 2005; 352(13): 1293 - 1304. [Abstract] [Full Text] [PDF]

Rapid Responses: